A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Phase 1 Recruiting 72 enrolled Granular Therapeutics Limited

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.

Timeline

Start: 2025-10-06
Primary completion: 2027-08
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GTX-B001	Unknown	—	Intravenous

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Summary

Timeline

Drugs

Indications